The Supreme Court has allowed mail delivery of the abortion medication mifepristone to continue, meaning patients across the United States can still receive the treatment by mail for now. The court’s action preserves current access while further legal review proceeds.
What happened
– The high court intervened to maintain the status quo on mail distribution of mifepristone. The move ensures that prescriptions or pharmacy shipments already permitted under federal rules may continue to be sent to patients.
Why it matters
– Mifepristone is a key medication used in medication abortion regimens. Limiting or halting mail delivery could have reduced timely access for people in areas with fewer clinics or long travel distances. By preserving mail access, the court’s decision keeps that route open while the underlying legal questions continue.
What to watch next
– The court’s order is temporary in effect: it preserves mail access “for now” while litigation or regulatory review continues. Further rulings, lower-court decisions or regulatory actions could change the landscape later.
Reporting
– CBS News’ Katrina Kaufman reported on the Supreme Court’s action and its immediate effect of keeping nationwide mail access to mifepristone in place.